Originalartikel | erschienen - Druck | peer reviewed
Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes?
BMC Endocrine Disorders
2013 ;
13(1):
12 -
Bibliometrische Indikatoren
Impact Factor = 1,673
Zitierhäufigkeit nach WOS = 22
DOI = 10.1186/1472-6823-13-12
PubMed-ID = 23517652
Beteiligte Einrichtungen
Abstract
BACKGROUND: To investigate potential associations of serum prolactin concentration (PRL) with metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM), previously observed in small and selected study samples, in a large population-based cohort. METHODS: Data from 3,993 individuals (2,027 women) aged 20-79 years from the population-based Study of Health of Pomerania (SHIP) were used to analyse cross-sectional and longitudinal associations of PRL with MetS and T2DM risk in age- and multivariable-adjusted Poisson regression models. PRL were log-transformed and modelled as continuous (per standard deviation (SD) increase) and categorical predictor (sex-specific quartiles) variable, separately for men and woman. RESULTS: Cross-sectional analyses showed an inverse association between low PRL concentrations and prevalent T2DM risk in men and women after multivariable-adjustment (men: Q1 vs. Q4: relative risk (RR), 1.55; 95% confidence interval (CI), 1.13 -- 2.14; women: Q1 vs. Q4: RR, 1.70; 95% CI, 1.10 -- 2.62). Likewise, higher PRL concentrations were associated with significantly lower T2DM risk (RR per SD increase in log-PRL: 0.83; 95% CI, 0.72 -- 0.95 in men, and 0.84; 95% CI, 0.71 -- 0.98 in women, respectively). An inverse association between PRL and MetS risk was not retained after multivariable adjustment. Longitudinal analyses yielded no association of PRL with incident MetS or T2DM. CONCLUSION: The present study is the first large population-based study reporting a cross-sectional inverse association between PRL and prevalent T2DM in both genders. But the absent longitudinal associations do not support a causal role of PRL as a risk factor of incident MetS or T2DM.
Veröffentlicht in
BMC Endocrine Disorders
| Jahr | 2013 |
| Impact Factor (2013) | 1,673 |
| Volume | 13 |
| Issue | 1 |
| Seiten | 12 - |
| Open Access | nein |
| Peer reviewed | ja |
| Artikelart | Originalartikel |
| Artikelstatus | erschienen - Druck |
| DOI | 10.1186/1472-6823-13-12 |
| PubMed-ID | 23517652 |
Allgemeine Daten zur Fachzeitschrift
Kurzbezeichnung: BMC ENDOCR DISORD
ISSN: N/A
eISSN: 1472-6823
Land: ENGLAND
Sprache: English
Impact Factor Entwicklung
ISSN: N/A
eISSN: 1472-6823
Land: ENGLAND
Sprache: English
Impact Factor Entwicklung
| Jahr | Impact Factor |
|---|---|
| 2011 | 2,163 |
| 2012 | 2,65 |
| 2013 | 1,673 |
| 2014 | 1,71 |
| 2015 | 1,739 |
| 2016 | 2,275 |
| 2017 | 2,027 |
| 2018 | 1,816 |
| 2019 | 1,994 |
| 2020 | 2,763 |
| 2021 | 3,263 |
| 2022 | 2,7 |
| 2023 | 2,8 |
| 2024 | 3,3 |
Projekte
GANI_MED Greifswald Approach to Individualized Medicine (Projektverbund)
FAQs | Impressum | Datenschutz

